Unlocking Potential: Oragenics Inc's Cutting-Edge Approach to Fighting Diseases
May. 2, 2024
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.
Visit RedChip.com to learn more.
